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While pharmacological methods are the mainstay for transplant immunosuppression, cell-
based therapies are being increasingly studied as a potential alternative. Currently available 
immunosuppressive medications lack specificity leaving transplant recipients vulnerable to 
infection, malignancy, and drug related toxicities while still being susceptible to chronic 
rejection. Donor-specific tolerance would be clearly superior to global immunosuppression 
yet remains an elusive goal. Recent advances in cell-based therapies along with an improved 
understanding of central and peripheral tolerance mechanisms offer new possibilities for 
donor-specific immunomodulation. Amongst the many types of cell-based therapies tested to 
date some of the most successful thus far have involved donor stem cell transplantation in 
living-donor kidney transplant recipients1. However, the need ex vivo cell manipulation 
along with T cell depletion and bone marrow conditioning makes these methods arduous for 
many transplant recipients, and impractical for those receiving deceased donor organs. As an 
alternative cellular therapy, dendritic cells (DCs) are particularly attractive because of their 
role as central regulators of immune responses2.
In this edition of Transplantation, Dr. Rosen and colleagues3 present a comprehensive 
review of the role DCs play in producing allograft tolerance, highlighting recent studies 
demonstrating the utility of recipient-derived DCs loaded with donor antigen, rather than 
donor-derived DCs for transplant immunotherapy. Recipient-derived DCs present donor 
antigen in the context of self-MHC (indirect presentation), which in the setting of 
transplantation produces stronger allospecific effector responses when compared to direct 
presentation of donor MHC.4 Thus autologous DCs are attractive as they also generate 
potent regulatory T cell responses when compared to suppressive macrophages or myeloid 
derived suppressor cells.5 Murine models of allotransplantation demonstrate that these 
effects further extend graft survival with minimal pharmacologic immunosuppression.6,7,8 
Self-DCs may also be easier to maintain in an immature phenotype after transfer as they will 
not themselves be targeted by pathways of direct antigen presentation that can lead to their 
elimination or, even worse, induce their maturation and sensitize the recipient against donor 
antigen.
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As illustrated in the review by Rosen et al, the surface phenotype and location of DCs 
influence their effects on the immune system. Considered to be the most potent of the 
antigen presenting cell types, DCs are highly mobile sentinels of the innate immune system 
that collect peripheral antigens and present them to the adaptive immune system. The 
context in which DCs present antigen is regulated by a complex array of stimulatory and 
inhibitory signals that orchestrate the direction and magnitude of the immune response. In 
the presence of local inflammatory signals, tissue resident DCs mature (mDCs) and express 
increased levels of antigen presenting molecules, costimulation molecules, and 
inflammatory cytokines that differentiate T cells into effector phenotypes. In the absence of 
inflammation, immature DCs (imDCs) including migratory conventional DCs (SIRPα+, 
CD11c+, B220neg) and plasmacytoid DCs (PDCA-1+, CD11c+, B220+) with decreased 
antigen presenting potential, help maintain self-tolerance to peripheral antigens.
While the migratory routes of DCs are incompletely understood, there is evidence that their 
phenotype governs their destination and ultimately their function in regulating immune 
responses (Figure 1). In the setting of inflammatory signals, mDCs in the periphery also 
upregulate chemokine receptors (eg, CCR7 and CXCR4) and adhesion molecules (eg, 
LFA1). DCs expressing CCR7 and CXCR4 chemotaxis to LNs through attraction by their 
ligands (CCL21 and CCL19, and CXCL12, respectively) and LFA1/ICAM-1 interactions 
which are critical to DC adherence and residence in LNs where they stimulate and polarize 
T cells.9,10 However, the roles of these molecules are complex and ‘semimature’ DCs 
expressing CCR7, yet low levels of CD40 and B7 have been found to have a role in steady 
state migration of skin DCs even in the absence of inflammation.11
As discussed by Rosen et al, intrathymic imDCs can produce tolerogenic responses. In the 
absence of inflammation, imDCs that express CCR9 and CCR2, but have low levels of 
CCR7 and CXCR4, can bypass the lymph nodes en route to the central venous system. The 
circulating imDCs can then home to the thymus driven by CCR9/CCL25 interactions12 and 
migrate into the thymus though processes involving VLA4 and its ligand VCAM-112,13. 
While the thymus has mechanisms for maintaining self-tolerance through its intrinsic 
expression of peripheral self-antigens regulated by the autoimmune regulator (AIRE) 
protein14, peripheral sampling of self-antigens by immature DCs provides a supplemental 
mechanism for maintaining tolerance to peripheral tissue antigens15. The question remains 
whether these tolerance mechanisms can translate into effective cellular therapies for clinical 
transplantation.
If DC localization and function is determined by phenotype, then methods of isolating and 
preparing recipient DCs with the appropriate markers is critical to determining their capacity 
for immune modulation. The studies presented in the review by Rosen et al demonstrate the 
potential for DC based tolerance induction. Although clearly demonstrated in murine 
models, further mechanistic understanding in the human immune system is needed to 
translate these concepts into clinical feasibility, whether they be for the purpose of immune-
inhibition in transplantation and autoimmune disease, or immune-stimulation for tumor 
therapy.16 Already the administration of autologous tolerogenic DC preparations are 
beginning to be testing in clinical trials for the treatment of autoimmune diseases15, and for 
immunosuppressive therapy in the setting of living-donor renal transplantation in the 
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European ONE Study17. However additional questions remain that may further improve 
efficacy in the setting of transplantation. These include refining methods for induction and 
maintenance of imDCs including ex vivo versus in vivo manipulation, the source for donor 
antigen, the incorporation of induction protocols, timing of therapy, and the durability of 
such cell-based treatments. As the marshals of the adaptive immune system, DCs hold 
significant potential for cell-based immune therapies. Further clinical studies will be 
required to determine if these concepts and methods can effectively translate to the human 
immune system which can vary greatly between individuals based on their immunologic 
history and physiology.
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Abbreviations
AIRE Autoimmune regulator
CCR7 C-C chemokine receptor type 7
CCR9 C-C chemokine receptor type 9
CCL19 C-C motif chemokine ligand 19
CCL21 C-C motif chemokine ligand 21
CCL25 C-C motif chemokine ligand 25
CXCL12 C-X-C motif chemokine ligand 12
CXCR4 C-X-C chemokine receptor type 4
DC Dendritic cell
ICAM-1 Intercellular adhesion molecule 1
imDC Immature dendritic cell
mDC Mature dendritic cell
LFA1 Lymphocyte function-associated antigen 1
MHC Major histocompatibility complex
VCAM-1 Vascular cell adhesion molecule 1
VLA4 Very late antigen 4
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Figure 1. Dendritic cell phenotype governs localization and function
Inflammatory signals in peripheral tissues cause DC activation and maturation into mDCs. 
Based on the upregulation of specific chemokine receptors and adhesion molecules, mDCs 
traffic to lymph nodes and promote immune stimulation. Circulating from healthy peripheral 
tissues, imDCs can bypass lymph nodes and migrate to the thymus and promote immune 
tolerance to peripheral antigen. Illustrated by Megan Llewellyn, MSMI; copyright Duke 
University; with permission under a CC BY-ND 4.0 license
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